Author Correction: The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine.
Saved in:
| Title: | Author Correction: The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine. |
|---|---|
| Authors: | Escudero I; Takeda Vaccines, Inc., Boston, MA, USA. ian.escudero@takeda.com., Gniel D; Takeda Pharmaceuticals International AG, Zurich, Switzerland., Biswal S; Takeda Vaccines, Inc., Boston, MA, USA., Petri E; Takeda Pharmaceuticals International AG, Zurich, Switzerland., Perez G; Takeda Vaccines, Inc., Boston, MA, USA., Sharma M; Takeda Vaccines, Inc., Boston, MA, USA., Weil J; Takeda Pharmaceuticals International AG, Zurich, Switzerland., Wallace D; Takeda Vaccines, Inc., Boston, MA, USA. |
| Source: | NPJ vaccines [NPJ Vaccines] 2026 May 06; Vol. 11 (1). Date of Electronic Publication: 2026 May 06. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2059-0105 |
|---|---|
| DOI: | 10.1038/s41541-026-01471-3 |
